Instant Download RAPS: RAC-GS Free Updated Test Dumps
Valid RAC-GS FREE EXAM DUMPS QUESTIONS & ANSWERS
RAPS RAC-GS (Regulatory Affairs Certification (RAC) Global Scope) Exam is a certification program designed for regulatory affairs professionals who are looking to enhance their knowledge and credibility in the field of regulatory affairs. Regulatory Affairs Certification (RAC) Global Scope certification is globally recognized and serves as a benchmark for regulatory professionals across the world. RAPS RAC-GS is a comprehensive exam that covers a wide range of regulatory topics, including global regulatory requirements, regulatory strategies, regulatory submissions, and regulatory compliance.
The RAC-GS certification is an internationally recognized credential that signifies a professional's commitment to excellence in regulatory affairs. RAC-GS exam is designed to test a candidate's knowledge and skills in a variety of areas related to global regulatory requirements, product development, regulatory submissions, and post-market surveillance. Regulatory Affairs Certification (RAC) Global Scope certification is highly valued by employers and regulatory agencies around the world, and it provides regulatory professionals with access to a variety of networking and professional development opportunities. If you are a regulatory professional who is looking to advance your career in the field of regulatory affairs, the RAC-GS certification may be the credential you need to take your career to the next level.
The RAC-GS exam is a specialized version of the RAC exam that is designed for regulatory professionals who work in a global regulatory environment. RAC-GS exam covers a wide range of topics that are relevant to regulatory professionals who work in different regions of the world. RAC-GS exam is suitable for regulatory professionals who work in various sectors of the healthcare industry and is a rigorous assessment that requires candidates to demonstrate their knowledge and skills in various areas of global regulatory affairs.
NEW QUESTION # 15
In which section of the ICH Common Technical Document will the overview of clinical data appear?
- A. Module 2
- B. Module 3
- C. Module 1
- D. Module 4
Answer: A
NEW QUESTION # 16
According to ICH, what is the MAXIMUM amount of time in calendar days that an organization has from
the initial receipt of information to report serious and unexpected ADR of a marketed product to regulatory
authorities?
- A. 0
- B. 1
- C. 2
- D. 3
Answer: A
NEW QUESTION # 17
During the review of a design dossier, the reviewer asks why the company has only carried out a
top-down risk approach. The reviewer is referring to which of the following?
- A. Fault tree analysis
- B. Failure mode and effect analysis
- C. Hazard and operability study
- D. ISO 14971 risk analysis
Answer: D
NEW QUESTION # 18
A process is ultimately validated to ensure which of the following?
- A. The process meets the regulatory requirements.
- B. The process consistently produces the desired results.
- C. The process consistently meets the desired Quantity standards
- D. The process meets the quality system requirements.
Answer: B
NEW QUESTION # 19
Which of the following statements regarding export regulations for an approved product is CORRECT?
- A. The product must not be labeled on the outside of the shipping package that it is intended for export.
- B. The product must not be sold or offered for sale in domestic commerce.
- C. The product must not be in conflict with the laws of the country to which it is intended for export.
- D. The product must not be in accord with the specifications of the foreign purchaser.
Answer: C
NEW QUESTION # 20
The regulatory authority contacts the regulatory affairs professional regarding a complaint about a drug
produced by the company. A consumer reported to the regulatory authority that the tablets have a slightly
different color and break easily.
Which of the following actions should the regulatory affairs professional take?
- A. Respond to the regulatory authority that the company will provide copies of the relevant QC records for
batch release. - B. Ask that the regulatory authority provide the actual product subject to the complaint.
- C. Ask that the regulatory authority provide the batch number printed on the packaging of the affected
product. - D. Respond to the regulatory authority that the product subject to the complaint is most likely a counterfeit
product.
Answer: C
NEW QUESTION # 21
Which of the following criteria is MOST appropriate to define the animal species needed for the
pre-clinical toxicity testing of a biotechnology product?
- A. Biological activity with species and/or tissue specificity
- B. Proposed dose and volume of administration
- C. Immunochemical and functional tests
- D. Proposed product route and frequency of administration
Answer: A
NEW QUESTION # 22
A regulatory affairs professional has submitted a package for regulatory review. According to the
regulation, the regulatory authority will need to respond within 90 days of submission. If there is no
response after the deadline, what is the BEST approach?
- A. Contact the company legal representative in order to begin legal proceedings to enforce the regulatory
authority's response time. - B. Contact the local political representative and ask for intervention with the regulatory authority to obtain
a decision regarding the submission. - C. Contact the regulatory authority, ask for clarification about the delay, and provide answers to any
outstanding questions. - D. Contact the regulatory authority, ask for clarification about the delay, and demand a decision be made
regarding the submission.
Answer: C
NEW QUESTION # 23
Which of the following is an example of an acceptable statement for an advertisement of an approved
arthritis medication?
- A. "Product X is safe for arthritis and without side effects."
- B. "Product X is a guaranteed cure for arthritis."
- C. "Product X is effective in all patients with arthritis."
- D. "Product X is effective for the treatment of arthritis."
Answer: D
NEW QUESTION # 24
A company is preparing the submission package for a drug to be registered in international markets.
When preparing the legal documentation, which document MUST comply with the WHO
recommendations?
- A. Certificate of Pharmaceutical Product
- B. Certificate of Analysis for the finished product
- C. Certificate of Free Sale
- D. Certificate of GMP
Answer: A
NEW QUESTION # 25
In addition to protection, what parameters MUST be considered when selecting the primary package (or a
product?
- A. Compatibility and safety
- B. Volume and material
- C. Efficacy and material
- D. Safety and efficacy
Answer: A
NEW QUESTION # 26
Which of the following BEST describes the content of the "Physical, Chemical, and Pharmaceutical
Properties and Formulation" section of an IB?
- A. A review of available data to support the determination of the chemical structure and physical attributes
of the drug substance plus batch analysis and stability data for the finished formulation - B. A detailed summary of the physical and chemical properties of the drug product with a signed expert
statement addressing the suitability and stability of the formulation for its intended use - C. A brief summary of relevant physical, chemical, and pharmaceutical properties: instructions for storage
and handling of the dosage form: and a description of the formulation - D. A description and flow chart illustrating the synthetic route for the active ingredient and the preparation
method of the finished product
Answer: C
NEW QUESTION # 27
An inspection of a manufacturing site determines that a number of manufacturing changes have been
implemented without obtaining the necessary regulatory clearance. Which of the following actions should
the regulatory affairs professional complete FIRST?
- A. Stop product manufacturing.
- B. Assess the impact of the changes.
- C. Establish validation procedures.
- D. Review the stability data for the changes.
Answer: A
NEW QUESTION # 28
Which of the following is MOST appropriate for the purpose of lot release of biologics?
- A. Inventory control
- B. Quality verification
- C. Safety assurance
- D. Efficacy confirmation
Answer: B
NEW QUESTION # 29
After submission to the regulatory authority, a substantial error was found in the application. In order to
resolve this issue, what should be done FIRST?
- A. Inform upper management immediately.
- B. Verify the procedure in the regulation for the corrections.
- C. Contact the legal department and ask them how to proceed.
- D. Resubmit the entire package.
Answer: B
NEW QUESTION # 30
According to the ICH guideline on GMP for API, to which of the following is the MOST stringent
requirement applied?
- A. Production of Intermediate(s)
- B. Introduction of the API starting material
- C. Isolation and purification
- D. Physical processing and packaging
Answer: D
NEW QUESTION # 31
At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the
manufacturing process. Which of the following stakeholders should be notified FIRST?
- A. Quality assurance
- B. Clinical affairs
- C. Regulatory agency
- D. Quality improvement
Answer: A
NEW QUESTION # 32
A global company has obtained a patent in a specific country for a newly marketed product. What would
be the BEST advice In order to protect the patent in other countries?
- A. File design patents in target countries.
- B. File patents of interest in target countries.
- C. Use the community patent system.
- D. Use the Madrid system.
Answer: B
NEW QUESTION # 33
A drug product presents degradation during the manufacturing process. In addition to the amount, what
information should be provided FIRST in order to use API overage?
- A. Justification
- B. Formulation
- C. Specification
- D. Property
Answer: A
NEW QUESTION # 34
According to ICH, how many stability time points are normally required to establish a two-year shelf life for
a product?
- A. 0
- B. 1
- C. 2
- D. 3
Answer: C
NEW QUESTION # 35
Who has the PRIMARY responsibility for recall of products with quality defects?
- A. Regulatory authority
- B. Distributor
- C. Consumer
- D. Manufacturer
Answer: D
NEW QUESTION # 36
......
Free RAC-GS Exam Braindumps RAPS Pratice Exam: https://www.examcollectionpass.com/RAPS/RAC-GS-practice-exam-dumps.html